Arrowhead Pharmaceuticals (ARWR) Price & Analysis

Compare

1,522 Followers

ARWR Stock Chart & Stats

Day’s Range― - ―

52-Week Range$9.57 - $30.41

Previous CloseN/A

Volume680.40K

Average Volume (3M)1.69M

Market Cap

$2.17B

Enterprise Value$3.46B

Total Cash (Recent Filing)$552.93M

Total Debt (Recent Filing)$525.27M

Price to Earnings (P/E)―

Beta2.35

Next Earnings

Aug 11, 2025

EPS Estimate

-0.95

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)2.75

Shares Outstanding138,100,430

10 Day Avg. Volume1,481,231

30 Day Avg. Volume1,692,561

Financial Highlights & Ratios

PEG Ratio-0.87

Price to Book (P/B)32.88

Price to Sales (P/S)0.00

P/FCF Ratio-18.44

Enterprise Value/Market Cap1.59

Enterprise Value/Revenue56.53

Enterprise Value/Gross Profit-287.15

Enterprise Value/Ebitda-1.65

Forecast

1Y Price Target

$41.00

Price Target Upside164.52% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering11

Arrowhead Pharmaceuticals News

See All News >

Bulls Say, Bears Say

Bulls Say

Drug ApprovalThe FDA accepted the NDA for plozasiran to treat familial chylomicronemia syndrome, setting up Arrowhead for its first approved drug.

Financial PositionArrowhead is well-capitalized with $1.1 billion in cash, funded into 2028, and started to pay down the $400 million term loan with cash inflows from the collaboration.

Market PotentialThe upcoming launch of plozasiran is expected to pave the way for entry into the larger SHTG market, which has significant potential sales.

Bears Say

Regulatory ProcessManagement does not expect ongoing changes in Washington to affect the timing of plozasiran approval.

Stock Price LimitationThere is a low ceiling for shares in the short term due to limited upside for the FCS launch.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

4.24% Insiders

15.44% Mutual Funds

21.20% Other Institutional Investors

33.60% Public Companies and Individual Investors

Detailed Ownership Overview >

ARWR FAQ

What was Arrowhead Pharmaceuticals’s price range in the past 12 months?

Arrowhead Pharmaceuticals lowest stock price was $9.57 and its highest was $30.41 in the past 12 months.

What is Arrowhead Pharmaceuticals’s market cap?

Arrowhead Pharmaceuticals’s market cap is $2.17B.

When is Arrowhead Pharmaceuticals’s upcoming earnings report date?

Arrowhead Pharmaceuticals’s upcoming earnings report date is Aug 11, 2025 which is in 54 days.

How were Arrowhead Pharmaceuticals’s earnings last quarter?

Arrowhead Pharmaceuticals released its earnings results on May 12, 2025. The company reported $2.75 earnings per share for the quarter, beating the consensus estimate of -$0.442 by $3.192.

Is Arrowhead Pharmaceuticals overvalued?

According to Wall Street analysts Arrowhead Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Arrowhead Pharmaceuticals pay dividends?

Arrowhead Pharmaceuticals does not currently pay dividends.

What is Arrowhead Pharmaceuticals’s EPS estimate?

Arrowhead Pharmaceuticals’s EPS estimate is -0.95.

How many shares outstanding does Arrowhead Pharmaceuticals have?

Arrowhead Pharmaceuticals has 138,100,430 shares outstanding.

What happened to Arrowhead Pharmaceuticals’s price movement after its last earnings report?

Arrowhead Pharmaceuticals reported an EPS of $2.75 in its last earnings report, beating expectations of -$0.442. Following the earnings report the stock price went up 9.377%.

Which hedge fund is a major shareholder of Arrowhead Pharmaceuticals?

Currently, no hedge funds are holding shares in ARWR

Arrowhead Pharmaceuticals Stock Smart Score

Underperform

Fundamentals

Return on Equity

-24.67%

Trailing 12-Months

Asset Growth

64.74%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. is a biotechnology company specializing in the development of RNA interference (RNAi) therapies. The company focuses on creating medicines that silence disease-causing genes, primarily targeting liver diseases, as well as other indications. Arrowhead's proprietary Targeted RNAi Molecule (TRiM) platform aids in the design and delivery of these therapies, allowing for precise targeting of specific cells and tissues. The company is headquartered in Pasadena, California, and operates within the broader biotechnology and pharmaceuticals sector.

ARWR Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Arrowhead Pharmaceuticals demonstrated strong financial performance and significant progress in its pipeline, particularly with the upcoming launch of Plozasiran and promising data from clinical trials. However, the company faces regulatory uncertainties and market challenges, with a heavy reliance on partnerships for future revenue. The sentiment is generally positive due to the outweighing highlights.Read More>

ARWR Stock 12 Month Forecast

Average Price Target

$41.00

▲(164.52%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","30":"$30","47":"$47","64":"$64","81":"$81"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$80.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$41.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,30,47,64,81],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Oct<br/>2024","9":"Jan<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.04,19.113846153846154,24.18769230769231,29.26153846153846,34.33538461538461,39.409230769230774,44.48307692307692,49.55692307692308,54.63076923076923,59.70461538461539,64.77846153846154,69.8523076923077,74.92615384615385,{"y":80,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.04,16.113846153846154,18.18769230769231,20.26153846153846,22.335384615384616,24.40923076923077,26.483076923076922,28.556923076923077,30.630769230769232,32.70461538461539,34.77846153846154,36.85230769230769,38.92615384615385,{"y":41,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.04,14.267692307692307,14.495384615384614,14.723076923076922,14.95076923076923,15.178461538461537,15.406153846153845,15.633846153846154,15.861538461538462,16.08923076923077,16.316923076923075,16.544615384615383,16.77230769230769,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":28.24,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.17,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.95,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.05,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.46,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.83,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.18,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.49,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.34,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.8,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.88,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.91,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.04,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >